Bharat Biotech's Covaxin- a vaccine against Covid-19 was
given approval by Drugs and Controller General of India (DCGI) for restricted
use in emergency situations. It has proven to be safe and triggers immune
response in a small group of people between 18-55 years age, as per the study published
in The
Lancet medical journal.
Read More: Are you going to take Covaxin shot? Learn what consent form says
The use of Covaxin has been allowed under "clinical trial mode." As per the consent letter of the vaccine, the "COVAXINTM" has been permitted in public interest for restricted use in emergency situations.
According to a report published in Reuters, Bharat
Biotech's vaccine is being tested on separate 25, 800 person trial since
November. Bharat Biotech said, 13,000 people participating in the late-stage of
trial has been given the second dose.
Read More: Covaxin: Bharat Biotech explains side-effects, who shouldn't take it
It is the interim data published in the journal that included three different vaccine formulations and a placebo group among 375 adults. Two formulations termed COVAXIN have been taken for more advanced stage of testing and further efficacy trials are warranted, the report said.